Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Nov;48(11):4453-6.
doi: 10.1128/AAC.48.11.4453-4456.2004.

In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies

Giovanni Di Bonaventura  1 , Ilaria Spedicato, Carla Picciani, Domenico D'Antonio, Raffaele Piccolomini
Affiliations

In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies

Giovanni Di Bonaventura et al. Antimicrob Agents Chemother. 2004 Nov.

Abstract

Time-kill and postantifungal effect (PAFE) of amphotericin B, caspofungin, fluconazole, and voriconazole were determined against clinical isolates of Candida guilliermondii, Candida kefyr, and Candida lusitaniae. Azoles displayed fungistatic activity and no measurable PAFE, regardless of the concentration tested. Amphotericin B and caspofungin demonstrated concentration-dependent fungicidal activity, although amphotericin B only produced a significant dose-dependent PAFE against all isolates tested.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Representative time-kill plots for the following: AMB against C. guilliermondii 337 (A) and C. lusitaniae 447 (B); caspofungin against C. kefyr 270 (C); and VRC against C. lusitaniae 325 (D). Antifungals were tested at the following concentrations: 0.125 times the MIC (▴), 0.25 times the MIC (▾), the MIC (⧫), 4 times the MIC (•), and 8 times the MIC (□). ▪, control.
See this image and copyright information in PMC

References

    1. Cheng, M. F., K. W. Yu, R. B. Tang, Y. H. Fan, Y. L. Yang, K. S. Hsieh, M. Ho, and H. J. Lo. 2004. Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999. Diagn. Microbiol. Infect. Dis. 48:33-37. - PubMed
    1. Chryssanthou, E., O. Cars, and J. Sjölin. 2002. New automated method for determining postantifungal effect of amphotericin B against Candida species: effects of concentration, exposure time, and area under the curve. Antimicrob. Agents Chemother. 46:4016-4018. - PMC - PubMed
    1. Clancy, C., M. Nguyen, and V. Yu. 1996. Fungemia caused by Candida lusitaniae. Infect. Med. 13:940, 948-951.
    1. Collin, B., C. J. Clancy, and M. H. Nguyen. 1999. Antifungal resistance in non-albicans Candida species. Drug Resist. Updat. 2:9-14. - PubMed
    1. Dick, J. D., R. R. Rosengard, W. G. Merz, R. K. Stuart, G. M. Hutchins, and R. Saval. 1985. Fatal disseminated candidiasis due to amphotericin B-resistant Candida guilliermondii. Ann. Intern. Med. 102:67-68. - PubMed

Publication types